Progressive Multifocal Leukoencephalopathy: Current Insights

Marge Kartau1
Jussi OT Sipilä2–4
Eeva Auvinen5
Maarit Palomäki6
Auli Verkkoniemi-Ahola1

1Clinical Neurosciences, Neurology, Helsinki University Hospital and Helsinki University, Helsinki, Finland;
2Department of Neurology, Siun Sote, North Carelia Central Hospital, Joensuu, Finland;
3Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland;
4Clinical Neurosciences, University of Turku, Turku, Finland;
5Department of Virology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;
6Neuroradiology, HUS Medical Imaging Center, Helsinki, Finland

Abstract: Cases of PML should be evaluated according to predisposing factors, as these subgroups differ by incidence rate, clinical course, and prognosis. The three most significant groups at risk of PML are patients with hematological malignancies mostly previously treated with immunotherapies but also untreated, patients with HIV infection, and patients using monoclonal antibody (mAb) treatments. Epidemiological data is scarce and partly conflicting, but the distribution of the subgroups appears to have changed. While there is no specific anti-JCPyV treatment, restoration of the immune function is the most effective approach to PML treatment. Research is warranted to determine whether immune checkpoint inhibitors could benefit certain PML subgroups. There are no systematic national or international records of PML diagnoses or a risk stratification algorithm, except for MS patients receiving natalizumab (NTZ). These are needed to improve PML risk assessment and to tailor better prevention strategies.

Keywords: progressive multifocal leukoencephalopathy, JC polyomavirus, monoclonal antibodies, HIV, multiple sclerosis, disease modifying therapies

Introduction

Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the central nervous system (CNS) first described in 1958 by Åström and colleagues.1 PML, named after its pathological features, is a progressive multifocal disease of white matter, which can now be thought of as the classical form of PML. The disease is caused by the JC polyomavirus (JCPyV). The prerequisite for PML is profound suppression of cell-mediated immunity, whether associated with diseases, such as HIV or lymphoproliferative malignancies, or treatment with immunosuppressive or immunomodulatory therapies (multiple sclerosis or rheumatoid arthritis) or both (systemic lupus erythematosus). Epidemiological data for different PML subgroups is scarce and partly conflicting because there are no systematic national or international records of PML diagnoses and only a few population-based studies of PML incidence. During the 1980’s and 1990’s with the emergence of HIV in humans, PML was the most important opportunistic infection of the CNS in these patients and most PML cases occurred in this group. In recent times, PML has been increasingly diagnosed in patients treated with biological therapies such as mAbs which deplete lymphocytes or impede leukocytes trafficking into the CNS. Interest in PML increased in 2005 when its association with the multiple sclerosis (MS) drug natalizumab (NTZ) was discovered2 and MS patients have become an important population at possible...
risk of PML.\textsuperscript{3} NTZ provides a good example how the risk-benefit profile must be determined at the individual level. PML risk also affects certain other MS therapies to a smaller degree. Other mAbs, as well as chemotherapy needed to treat patients with malignant diseases or after solid organ (SOT) or hematopoietic stem cell transplantation (HSCT) are also associated with an increased risk of PML.\textsuperscript{4}

PML diagnosis is based upon distinguishing neurological features, characteristic changes in brain magnetic resonance imaging (MRI), and the presence of JCPyV DNA in cerebrospinal fluid (CSF). Currently reconstitution of the immune system gives the best prognosis for this condition.

As the etiology of PML has changed, so have its diagnosis and management. The nature of immunosuppression underlying PML determines the prognosis, treatment, and the risk of PML immune reconstitution inflammatory syndrome (PML-IRIS). Detection of PML at an early stage, when the disease is asymptomatic and restricted, is associated with a better outcome and higher survival rate.\textsuperscript{5,6}

\textbf{JCPyV Infection}

JCPyV is a member of the \textit{Polyomaviridae} family and has a 5 kb double-stranded circular DNA genome. The initial route of infection is thought to be ingestion or respiratory inhalation. The virus is then transported into kidney epithelial cells, bone marrow and spleen, where it establishes life-long persistence. JCPyV also persists in the lymphocytes.

Primary asymptomatic infection usually occurs in childhood, but adult infections are also possible. Primary infection is caused by the so called “archetype” virus, where the non-coding control region (NCCR) has a certain block structure. Occasionally, in immunosuppressed but also in healthy individuals, asymptomatic reactivation of JCPyV may take place, and the virus is excreted in the urine. Upon active viral replication in immunosuppressed individuals rearrangements in the viral genome may emerge, which mainly affect the NCCR but occasionally also the VP1 viral capsid protein. The archetype virus does not replicate efficiently in the brain, whereas the so called neurotropic variants harboring NCCR rearrangements can actively replicate in glial cells. Mutations in VP1 may additionally favor virus tropism for alternative cell populations, increasing the risk of PML. Mutations within the large T antigen and agnoprotein genes have also been reported in both PML\textsuperscript{7,8} and non-PML patients.\textsuperscript{9}

Although most primary infections take place in childhood, the development of PML in childhood is extremely uncommon. JCPyV seroprevalence increases with age and reaches 90% in adults with occasional JCPyV shedding in urine within 19–27% of individuals.\textsuperscript{10} Each year 3% or less of the seronegative population becomes infected.\textsuperscript{11}

The rarity of PML despite the widespread prevalence of JCPyV implies robust barriers to the development of the disease. Cell-mediated immunity is crucial for controlling JCPyV, as reflected by the high rates of the disease in advanced HIV infection, especially when the CD4+ lymphocyte count is below 100 cells/mm\textsuperscript{3}. However, B cells and CD34+ progenitors also play roles in the pathophysiology, acting as viral reservoirs, and as a vector for viral dissemination in the CNS.\textsuperscript{12} B-cell depletion disrupts CD4- and CD8-positive T-cells homeostasis. Plasma cells regulate inflammatory T-cells activity via the immunosuppressive pathways, thereby protecting the brain from excessive immune-mediated damage during active JCPyV infection.\textsuperscript{13} The role of anti-JCPyV antibodies is not yet completely understood. As more than half of PML patients are seropositive before the onset of PML, humoral immune responses seem insufficient to protect the patient from developing PML. Altogether higher antibody levels have been detected in patients before PML diagnosis as compared to patients who did not develop PML.\textsuperscript{14} Increase in anti-JCPyV antibody levels in NTZ treated patients prior to or coinciding with PML diagnosis has been suggested in some studies,\textsuperscript{15,16} possibly associated with virus reactivation. Other studies report stable high anti-JCPyV antibody levels prior to PML, although the authors considered the possibility that an increase in antibody levels may have been hidden by antibody assay saturation.\textsuperscript{17}

PML is not the only disorder caused by JCPyV. Nephropathy with or without PML has been observed in renal allograft recipients.\textsuperscript{18} JCPyV can also infect meningeal and choroid plexus cells causing JCPyV meningitis (JCVM).\textsuperscript{19} There are reported cases of granule cell neuropathy (JCVGCN) of the cerebellum.\textsuperscript{20} Fulminant JCPyV encephalopathy (JCE), involving cortical pyramidal neurons, is characterized by infection and lysis of cortical gray matter.\textsuperscript{21} JCPyV has been found in the brain of otherwise healthy individuals\textsuperscript{22} and therefore the presence of the virus is insufficient to make a diagnosis of PML.

\textbf{Neuropathology}

Pathologic features in PML include demyelination with the presence of foamy macrophages, relative preservation of axons, and astrogliosis, sometimes with atypical astrocytic nuclei and opalescent oligodendroglial nuclei. These oligodendroglial nuclei are filled with virus particles when
viewed by electron microscopy, and the nuclei are consistently positive in immunohistochemistry using the monoclonal antibody to JCPyV, and in JCPyV in-situ hybridization (ISH). Neurons in the adjacent cortex can also become infected by the virus. Neurons in the adjacent cortex can also become infected by the virus.

**Epidemiology of PML**

Population-based studies on PML epidemiology are scarce and long-term overall incidence trends are largely unknown (Table 1). Most papers report incidence in specific patient populations because PML was rare among patients not infected with HIV up to the mid-2000s, also the risk has decreased among HIV-patients after introduction of highly active antiretroviral therapy (HAART). A recent population-based Swedish study reported that after two decades of stable PML incidence of 0.026/100,000 person-years, the incidence has increased to 0.11 in 2011–2013, apparently related to the use of mAb therapies. Finnish population-based registry study investigating the period 2004–2014 reported an overall lower PML incidence of 0.072/100,000 person-years with no temporal incidence trend despite the increasing use of mAbs at the national level. In the most recent study from southern Finland in 2004–2016, we reported a PML-incidence of 0.12/100,000 person-years with no sign of increase. In this study the data was obtained from clinical records and the HIV Quality Registry. The discrepancy in incidence trends may be explained by differences in national circumstances and research methods. Nevertheless, they indicate that more studies from different regions and with in-depth analysis of PML causes are needed. Moreover, national PML surveillance and recording protocols would be helpful.

**Underlying Diseases**

**Hematologic and Oncologic Conditions**

PML was originally described in untreated patients with chronic lymphocytic leukemia (CLL) and Hodgkin’s disease. Currently patients with malignancies are the largest PML population, see Figure 1. PML can still occur in untreated patients but is more commonly associated with immunosuppressive or immunomodulatory treatments. Increased use of mAbs and HSCT correlate with rising PML incidence among patients with hematologic malignancies. Hematologic conditions associated with PML include CLL, Hodgkin’s disease, non-Hodgkin’s lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, Waldenström macroglobulinemia, multiple myeloma, polycythemia vera, and mycosis fungoides. Major PML risk factors are

| Table 1 Incidence Rate of PML in Different Populations |
|----------------|----------------|----------------|----------------|---------------|
| Population                  | Period            | Country          | Incidence Rate                      | Reference |
| General population          | 2004–2016         | Southern Finland | 0.12 per 100,000 individuals per year | 28          |
| General population          | 2004–2014         | Finland          | Annual incidence 0.072/100,000 person-years | 27          |
| General population          | 1988–2013         | Sweden           | 0.026–0.11 per 100,000 individuals per year | 26          |
| AIDS patients               | 1996–2011         | Spain            | 14.8/1000 patients/year in 1996 to 2.6 in 2005 and 0.8 in 2011 | 25          |
| SLE patients                | 1998–2005         | US               | 4 per 100,000 | 43          |
| RA patients                 | 1998–2005         | US               | 0.4 per 100,000 | 43          |
| Connective tissue diseases patients (other than SLE and RA) | 1998–2005         | US               | 2 per 100,000 | 43          |
| B-cell CLL patients         | 1987–1991         | US               | 1.08 | 111          |
| Hodgkin’s disease patients  | 1970–1984         | Holland          | 0.46 | 112          |
uncontrolled Hodgkin’s disease, treatment with purine analogues, and treatments related to HSCT. The prognosis is on the same level as in HIV-PML, but worse than in PML associated with autoimmune disorders.

**HIV Infection**

Previously HIV was the underlying condition in approximately 80% of PML cases but in addition to improving survival, the HAART has reduced the incidence of HIV-PML (Table 1). Indeed, HIV’s share as the predisposing disease has been 16–31% in the recent Nordic studies (Figure 1). The median survival time of HIV-PML patients in Denmark increased from 0.4 years in 1995–1996 to 1.8 years in 1997–2006 and a recent study from Spain reported a 1-year survival of 55% (79% when CD4+ count was >100 cells/mm3 at diagnosis) and a 50% 3-year survival. Similarly, the recent 1-year survival rate of HIV-PML patients was 75% in Paris, France. In the recent Swedish study, HIV-PML was correlated with higher mortality compared to PML associated with autoimmune disease or a malignancy whereas the recent Finnish study reported similar survival in HIV-PML or a malignancy (66% at 1 year), albeit poorer than in PML associated with a connective tissue disorder. CD4+ lymphocyte counts of <200 cells/µl are a known PML risk factor in HIV patients although patients with CD4+ counts above that and/or receiving HAART may also be affected.

**Organ Transplantations**

PML is a known complication associated with bone marrow transplants and SOT. The risk of PML among heart or lung transplant recipients is comparable to the PML risk associated with NTZ treatment for MS (Table 1). The most important risk factor for PML is immunosuppressive medication to prevent graft rejection. Median time from transplantation to onset of PML is 27 months in solid organ vs 11 months in bone marrow recipients. The fatality rate is high, around 84%, and the 1-year survival rate is 56%.

PML has been described in patients with either autologous or allogenic stem cell transplantation. PML risk is present due to invasive conditioning regimens and prolonged immune suppression. Symptoms typically develop more than 1 month after HSCT and have been reported as late as several years post-transplantation. In the transplantation population (both SOT and HSCT), PML is mostly associated with fludarabine and RTX therapy.
Autoimmune Diseases (Other Than MS)
The number of PML cases connected to autoimmune disease has been increasing since 2006. PML is usually ascribed to the drugs used to treat these diseases. The incidence rates are shown in Table 1.

Of all rheumatologic conditions, systemic lupus erythematosus (SLE) has the highest PML risk. Most SLE patients who develop PML have been subjected to, or are under immunosuppressant therapy. While the main cause of PML in SLE patients is therapy-related, it is possible that SLE may increase PML risk itself. A role of lymphopenia has been suggested.

Other PML-associated rheumatic diseases are vasculitis, most notably Wegener granulomatosis, poly- and dermatomyositis, scleroderma, and rheumatoid arthritis (RA). There are reports of PML in patients with Sjögren syndrome and sarcoidosis with no prior immunomodulatory therapy, but with considerable lymphopenia. Rheumatological drugs that may cause PML are rituximab, methotrexate, leflunomide, and infliximab. In the recent nationwide studies, PML associated with an autoimmune disorder had a more favorable prognosis than PML associated with HIV or malignancy.

Idiopathic Immune Deficiency Syndromes
PML has been described in patients with several types of primary immunodeficiency disorders (PIDs). PIDs are rare inherited disorders, characterized by a wide range of systemic or genetic defects, mostly with combined B and T cell impairment. Idiopathic CD4+ T lymphocytopenia is the most commonly reported PID behind PML. Many PML cases are secondary to immunosuppressive treatments such as prolonged steroid therapy, RTX, azathioprine, or anti-TNF-α used to treat autoimmune, inflammatory, or proliferative PID complications. According to a study of 11 PID-PML patients, all patients but one died after a median of 8 months following PML diagnosis.

PML in the Setting of Minimal or No Immunodeficiency
Some cases of PML have been reported with less overt immunodeficiency, such as chronic kidney and liver diseases, type 2 diabetes mellitus, dementia. There is one histologically proven PML case each concerning a pregnant woman, and a woman prior to pregnancy without any known underlying immunodeficiency. There is no epidemiological data suggesting that pregnant MS patients or healthy women have a higher incidence of PML.

PML in the Setting of mAb Therapy and Other Immunomodulating Drugs
Monoclonal antibody therapeutics have dramatically improved the therapy of chronic inflammatory diseases and cancers. Some mAbs repress the immune system for long periods, and predispose the patient to opportunistic infections. In addition to NTZ, other mAbs associated with PML are efalizumab and RTX. Efalizumab was withdrawn from the market in 2009 due to its association with PML. The incidence of PML due to RTX treatment is estimated to be 1 case per 32,000. There is an increased risk of PML in patients with SLE (1 case per 4000 individuals) and RA (1 case per 25,000 individuals) treated with rituximab (RTX). Many other mAbs have also been reported as risk factors of PML (Table 2). Patients with PML related to mAb treatment may have different clinical picture compared to classic PML. Once PML is identified, the mAb must be discontinued without delay and removed by plasmapheresis.

In addition to mAb, numerous other drugs are associated with PML (Table 2). These drugs have differences in the incidence rate of PML, the nature of the underlying diseases being treated, and the time from starting treatment to the development of PML.

Risk of PML is associated with several disease modifying therapies (DMTs) for MS (Table 3). The mode of action of DMTs plays a role in causing PML. The best studied DMT associated to PML is NTZ, which is a mAb that inhibits the transmembrane leukocyte receptor α4 integrin. It prevents leukocyte adhesion to vessel walls and subsequent migration across the blood-brain barrier, resulting in immunosuppression within the CNS. The more the CNS compartment is immunocompromised, the greater the risk of PML. NTZ may also inhibit the retention of lymphocytes in bone marrow and spleen, thus leading to an increase of JCPyV-infected peripheral leukocytes and to a possible increase of the peripheral JCPyV load. As of September 3, 2019 there have been 825 confirmed PML cases (822 MS, 3 Crohn’s disease) according to latest Tysabry Safety Update information. The overall global incidence of PML in NTZ-treated patients is 4.08 per 1000 patients (95% CI 3.80 to 4.36 per 1000 patients). The duration of NTZ dosing prior to PML diagnosis ranged from 8 to 148 doses, and the mean duration of NTZ dosing at time of PML.
The mortality rate in NTZ-PML is 12–24%. Major risk factors for NTZ-PML are the presence of serum antibodies to JCPyV, history of prior immunosuppression, and a length of NTZ treatment greater than 2 years. A recently acknowledged risk factor is a patient age over 50 years. In elderly patients, risk of lymphopenia is higher because of age-related immunosenescence, characterized by lower levels and functionality of lymphocytes. Lower anti-JCPyV antibody levels, or index values, are associated with lower PML risk in patients without previous immunosuppressant treatment group. For anti-JCPyV antibody-negative patients, estimated PML risk is less than 0.07 per 1000 patients. The PML risk is small at antibody index values of 0.9 or less, and increases with index values greater than 1.5 in people treated with NTZ for more than 2 years. The cumulative risk of PML begins to increase after two years of treatment and the increase remains constant from year three to year six. In anti-JCPyV antibody-positive patients, the risk of PML over 6 years is 2.7% in patients with previous immunosuppressant use and 1.7% in those without.

Adjusted odds ratios of PML associated with DMTs in 2015–2017 were reported as follows: NTZ 115.72, fingolimod 4.98, RTX 3.22 and DMF 1.77. There is a potential risk of PML with ocrelizumab use. There are seven carry-over cases of PML with ocrelizumab and five reports suggestive of carry-over PML, though not
meeting AAN diagnostic criteria. All five cases had MRI findings compatible with PML. In addition a confounded case of ocrelizumab monotherapy associated PML of 78-year old MS patient is reported. The incidence rate of PML with fingolimod is 3.12 per 100,000 patient-years. DMF-PML cases are usually associated with drug-induced prolonged lymphopenia and age of ≥50 years. However, recently a DMF-PML case of a 39-year patient without repeated lymphocyte counts below 800 cells/µL was reported. One case of MS patient’s PML has been described reported in association with alemtuzumab. Several PML cases have been described in lymphoma patients receiving polychemotherapy including alemtuzumab, but lymphoma is a PML risk factor itself as well. A few PML cases have been described in patients treated intravenously with cladribine, but there have been no cases of PML with oral cladribine.

**Diagnosis of PML**

According to the consensus statement from the American Academy of Neurology, PML diagnosis requires clinical, imaging, and virological evidence to make a definite, probable, or possible PML diagnosis. The highest level of diagnostic certainty requires histopathologic confirmation, though this is a highly invasive procedure. Therefore, the presence of clinical and/or imaging findings in combination with JCPyV DNA in CSF is also considered diagnostic but in the most challenging cases, brain biopsy may be performed. Brain biopsy has sensitivity of 64–96% and specificity of 100% in PML.

**PML Clinical Features**

The clinical presentation of PML is heterogeneous. The symptoms result from brain lesions in corresponding areas. Clinical symptoms are not mandatory in the diagnosis of confirmed PML, because the disease may be asymptomatic at the beginning. Hemiparesis, ataxia, gait disturbance, visual deficits, and cognitive changes are prevalent with limb weakness being the most common in HIV- and MS-associated PML. Although rare, brain stem involvement causes the most severe symptoms. The disease is progressive and symptoms worsen over time.

There is subtle variation in the presentation of PML as determined by the underlying cause. In HIV-PML, 50–73% of the patients have predominant motor system findings, following cognitive and speech difficulties. In a recent German study of 142 NTZ-PML patients, 33.8% had cognitive and equally as many had motor symptoms, 26.8% had gait ataxia, 25.3% had speech and language problems, and 16.2% had vision deficits. Seizures may occur in up to one-third of the general PML population and are more frequent with juxtacortical and T1-hyperintense lesions on MRI.

**Brain Imaging**

Brain MRI imaging is the most important diagnostic tool for PML diagnosis. Frequent brain scans are recommended for early detection of PML in high-risk patients (those who have three risk factors for NTZ-PML and those who have not had immunosuppressant therapy, but have high serum anti-JCPyV ab index and more than two years of NTZ), because PML lesions in MRI can develop before clinical symptoms.

The typical imaging features of PML include predilection for the frontal and parieto-occipital regions and subcortical location involving U-fibers. Involvement of the overlying cortex has been increasingly reported. Corpus callosum or deep grey matter may be affected. Posterior fossa involvement has been reported, most commonly involving the cerebellum and middle cerebellar peduncles. Lesions have sharp borders toward gray matter contrasting with ill-defined borders toward white matter, and increased signal intensity on T2-weighted and diffusion-weighted images (DWI). T2-weighted imaging may demonstrate a microcyst or granular pattern. On T1-weighted images PML lesions are hypointense and well-defined, even if small in size. Usually there is no gadolinium enhancement on MRI, but 15% of HIV-PML, and 40% of NTZ-PML patients may exhibit hazy peripheral, sometimes punctate or nodular enhancement. Two types of inflammation have been reported in PML: fatal IRIS type and anti-JCPyV immunoreaction type. The latter is associated with good prognosis.

When mass effect and enhancement are prominent, one should suspect PML-IRIS, particularly when accompanied by clinical deterioration. Enhancement at the time of diagnosis correlates with decreased survival and greater clinical disability compared to those that do not enhance.

In NTZ-PML, imaging features can be associated with progression. Radiologically widespread disease at diagnosis is present in 71% of fatal cases. Asymptomatic cases of PML found on screening MRI have been associated with good clinical outcomes.

**Laboratory Diagnostics**

Detecting JCPyV DNA in CSF by highly sensitive PCR has great diagnostic value. With new ultrasensitive PCR techniques, the sensitivity is >95% and specificity is >97%. Despite the high sensitivity of PCR, a negative test result...
does not rule out PML, because viral loads can be very low (below 100 copies/mL), while most commercial tests are able to detect JCPyV DNA in excess of 200 copies/mL. In HIV-infected patients, the viral load in CSF is high and sufficient for diagnosis. HAART decreases viral load and makes laboratory-confirmed diagnosis difficult. In patients with MS or other autoimmune diseases, the viral loads are also low. This creates a need to take multiple CSF samples despite a clinically strong suspicion of PML due to initial samples being falsely negative.

Management and Surveillance of PML

There is neither a specific prophylaxis nor an effective anti-JCPyV treatment for PML. A number of drugs such as cytarabine, cidofovir, INF-alpha, melfloquine, mirtazapine, and topotecan were used in clinical trials without benefit. Currently the approach to treating PML is prompt immune reconstitution without causing IRIS.

In NTZ-PML patients, immune reconstitution is achieved by plasma exchange in order to remove NTZ from peripheral circulation. There is one study reporting the benefits of filgrastim (granulocyte-colony stimulating factor) in patients with NTZ-PML. In HIV-infected patients, optimization of HAART is the best therapeutic choice.

In a portion of the PML population, such as patients with hematological malignancies, immune reconstitution cannot be achieved. For these patients, blocking of pathways involving programmed cell death 1 (PD-1), a T-cell surface receptor that keeps the immune system from attacking the body’s own tissues, and its ligand is a new promising treatment option. Pembrolizumab and nivolumab, mAbs that both target PD-1, both seem to reduce immune responses by preserving and activating CD4+ and CD8+ T cells. Immune checkpoint inhibitors activate the immune system, and as a side effect they may exacerbate any underlying autoimmune disease. A controlled trial is needed to determine whether PD-1 inhibitors are indeed able to suppress JCPyV in PML patients, and which subgroups would benefit from the treatment. Recently, several new treatment methods, such as systemic cytokine administration (interferon-alpha, interleukin-2, and interleukin-7) and immunization by recombinant human anti-JCPyV VP1 mAbs, JCPyV-specific cytotoxic T lymphocyte therapy, cryopreserved BK virus-specific T cells, and JCPyV capsid protein conjugated with interleukin-7 for PML were reported.

The prognosis of PML has evolved over time, and prolonged survival rates are becoming more common in HIV- and NTZ-PML groups. The survival rate in these groups is currently 70–80%. A low viral load in the CSF, VP1 loop-specific polymorphism, a controlled inflammation mediated by CD4- and CD8-positive T cells, and plasma cells and a regulatory immune system are associated with good PML prognosis. Predictors of favorable outcomes in NTZ-PML cases are younger age, lower Expanded Disability Status Scale score prior to diagnosis, shorter diagnostic delay, and more localized brain lesions on MRI at the time of diagnosis. PML cases related to HSCT have longer time to diagnosis, better survival rates, and lower mortality rates compared to the cases associated with biological treatments or purine analogues.

In HIV-PML, complete recovery is not to be expected but one third of the patients may become healthy enough to have no functional disability. Patients with cerebellar lesions have a worse outcome due to gait ataxia and incoordination that precludes independent living. Of NTZ-PML survivors, 40% have severe, 47% moderate, and 13% mild disability.

PML-IRIS

In patients with a reversible cause of immunosuppression, re-establishment of immunocompetence may lead to an excessively overreactive immune response referred to as IRIS. The likelihood of developing PML-IRIS depends on the underlying disease. Approximately 20% of HIV-PML patients and most NTZ-PML patients treated with immunoadsorption develop IRIS.

IRIS is treated with corticosteroids, which have a profound impact on the virus-specific T-cell response, especially on JCPyV. Therefore, they should not be given before the onset of clinical or radiological signs of IRIS. Sometimes prolonged corticosteroid therapy and treatment with maraviroc, a CCR5 receptor antagonist, has been reported and may be warranted to prevent overshooting damage by IRIS. The observation is not yet confirmed in a large study.

PML-IRIS is a potentially disabling and fatal condition with a mortality rate of 28%. Fatal PML-IRIS is characterized by excessive cytotoxic CD8-positive T-cell infiltration in the brain. In PML with controlled inflammation, both T- and B-cell lineages appear cooperatively.

However, several studies have not been able to demonstrate significant differences in survival rates between PML with and without IRIS.
PML Prevention Strategies for MS Patients

The optimal PML mitigation strategy is prevention and appropriate surveillance. PML is associated with several drugs, but so far, a risk stratification algorithm has only been established for NTZ (Table 3). Prior to starting NTZ, patients must be risk-stratified for the presence of serum JCPyV antibodies. Antibody testing is recommended for all NTZ-treated JCPyV antibody negative patients every six months, and in the event of seroconversion their therapy should be changed. MRI screening every 3–4 months is recommended for patients who receive NTZ for ≥18 months while JCPyV seropositive. A yearly brain MRI is recommended for patients at low risk of PML (JCPyV seronegative). MRI screening every 3–4 months up to 12 months is suggested when switching from NTZ to fingolimod, DMF or alemtuzumab. 80 In a recent study by Ryerson et al, for anti-JCPyV antibody-positive MS patients, extended interval dosing of NTZ was associated with significantly lower PML risk than standard interval dosing. 107

The European Medicines Agency (EMA) recommends that a complete blood count should be performed before starting treatment with DMF, and every 3 months during treatment. A baseline brain MRI should be available as a reference. If during treatment the lymphocyte counts drop to low levels for more than 6 months, the doctor should consider discontinuation of DMF. 107 Similar EMA guidelines exist for fingolimod. Before introducing fingolimod treatment, a baseline MRI scan should be available as a reference. If PML is suspected, MRI should be performed immediately and treatment with fingolimod should be suspended until PML has been excluded. 109

Long-term safety risks of sequential multiple therapies are still unknown. Currently, succession of therapies for patients with relapsing-remitting MS is determined by disease activity, patient-, and drug-related factors. The risk–benefit ratio of DMTs should be regularly re-evaluated as it changes with duration of therapy. Neurologists must remain vigilant for signs and symptoms of PML when switching from MS therapies associated with PML to a new MS therapy. PML should be carefully excluded by clinical-, imaging, and CSF exams, especially when switching from NTZ or fingolimod to long-lasting B-cell depleting therapy.

Safety protocols for PML exist for the treatment of MS patients. Other patients, such as cancer and rheumatic diseases have been identifiﬁed, these subgroups of PML have different incidences and prevalences, as well as different clinical courses and prognoses. While often associated with a bad prognosis, in some cases PML may become inactive, leaving patients with permanent neurological deﬁcits. The mainstay of PML treatment is immune reconstitution including discontinuation of the inciting agent, and with some medications plasma exchange, although blocking of PD-1 and its ligand, as well as direct antiviral therapeutics are an active area of investigation. Diagnosis is challenging and may need repeated clinical judgement, CSF testing, and MRI.

There is no systematic national or international record of PML diagnoses, and no risk stratification algorithm except for NTZ. The long-term risk of multiple successive immunomodulatory and immunosuppressive therapies is unknown. Global database and recording systems were developed by the company producing NTZ in order to follow up the emergence of PML and other adverse events during NTZ treatment. Surveillance registries as well as analysis of real-world data to improve the assessment of PML risk and to tailor prevention strategies for other PML subgroups are urgently required as well. In addition to neurologists, physicians from other ﬁelds must be aware of PML risk associated with mAb and other drugs. Current information concerning drugs causing PML is mostly provided by pharmaceutical companies. Large nationwide studies on the incidence and prevalence of PML with respect to the underlying diseases and treatments would provide evidence that is more conclusive.

Disclosure

The authors report no conﬂicts of interest in this work.

References


60. Lehmann HC, Krüger K, Fink GR, Schroeter M. Progressive multifocal leuкоencephalopathy after interferon beta-1a monotherapy. J Neurol. 2015;262:3. doi:10.1007/s00415-014-7620-4


